BUCHANG PHARMA(SH:603858) Shang Hai Zheng Quan Bao·2025-08-07 19:00Core Viewpoint - The company held its 28th meeting of the 5th Board of Directors on August 7, 2025, where several key resolutions were passed, including signing an exclusive supply agreement with GOODFELLOW for the drug Efparepoetin alfa, transferring equity in a subsidiary, and changing the registered address and name of another subsidiary [1][2][12]. Group 1: Exclusive Supply Agreement - The company’s subsidiary, Sichuan Luzhou Buchang Biological Pharmaceutical Co., Ltd., plans to sign an exclusive supply agreement with GOODFELLOW PHARMA CORPORATION, granting GOODFELLOW exclusive agency rights in the Philippines for the registration, clinical trials, promotion, distribution, and sales of Efparepoetin alfa [2][19]. - The agreement aims to enhance the company's international strategy and brand influence, facilitating the transition of research outcomes into economic benefits [32]. - The total R&D investment in Efparepoetin alfa as of June 30, 2025, is approximately 498.92 million yuan [21]. Group 2: Equity Transfer - The company plans to transfer 2% of its equity in its subsidiary, Jinan Buchang Caigan Trading Co., Ltd., to various individuals for a nominal price of 0 yuan, resulting in a reduction of the company's ownership from 93% to 90% [5][35]. - This transaction does not constitute a related party transaction or a major asset restructuring, and it does not require shareholder approval [35][36]. Group 3: Change of Registered Address and Name - The registered address and name of Jinan Buchang Caigan Trading Co., Ltd. will be changed due to operational needs, with the new address located in Zhuhai, Guangdong Province, and the new name being either "Buchang Qingsong Health (Hengqin) Co., Ltd." or "Buchang Forest Health (Hengqin) Co., Ltd." [12][8]. - The management has been authorized to handle all necessary procedures for this change [13].